NASDAQ · FULC
Fulcrum Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for FULC: Nov 4, 2026
Fulcrum Therapeutics, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.1. The reported EPS for the same quarter last year was $-0.31.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.10 | $-0.08 | $-0.13 | 2 |
| Dec 2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · BNK Invest · MarketBeat- Fintel · Oct 2, 9:57 AM EDTFulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75The average one-year price target for Fulcrum Therapeutics (NASDAQGM:FULC) has been revised to $7.75 / share. This is an increase of 11.22% from the prior estimate of $6.97 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not c
- RTTNews · Aug 27, 8:23 AM EDTSlate Doses First Participant In Phase 1 Study Of SLTE-1009; Topline Data Anticipated Mid-2027(RTTNews) – Slate Medicines announced that the first participant has been dosed in its Phase 1 clinical trial evaluating SLTE-1009, a therapy designed to expand treatment options for patients with advanced solid tumors. The milestone comes as Slate prepares to merge with Fulcrum
- RTTNews · Aug 21, 10:17 AM EDTWeekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks(RTTNews) – This week's global biopharma roundup captured a mix of regulatory approvals, strategic partnerships, acquisitions, and merger activity, alongside clinical trial breakthroughs and halts. Positive readouts across autoimmune myositis, glioma, and melanoma were offset by
- BNK Invest · Aug 17, 3:46 PM EDTNotable Monday Option Activity: FULC, BAC, VIAVLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Fulcrum Therapeutics Inc (Symbol: FULC), where a total volume of 11,758 contracts has been traded thus far today, a contract volume which is representative of ap
- MarketBeat · Aug 17, 9:02 AM EDTFulcrum Therapeutics Merges With Slate in $245M Migraine Biotech DealFulcrum Therapeutics (NASDAQ:FULC) has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing
- RTTNews · Aug 17, 7:46 AM EDTFulcrum-Slate Merger Announced; $245M Financing Boosts Migraine Pipeline; Shares Rise(RTTNews) – Fulcrum Therapeutics, Inc. (FULC) and Slate Medicines, Inc. announced that they have entered into a definitive all-stock merger agreement to form a combined company focused on next-generation migraine therapies. Upon completion, the entity will operate under the nam
- BNK Invest · Jul 16, 11:23 AM EDTThursday 7/16 Insider Buying Report: FULC, ECATAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. At Fulcrum Therapeutics, a filing with the SEC revealed that on Wednesday, Kevin T
- RTTNews · Jun 5, 10:26 AM EDTWeekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN(RTTNews) – This week, the biotech sector saw a wave of regulatory approvals in the U.S., alongside study halts, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical study data readouts spanned multiple therapeutic areas, inclu
- Zacks · Jun 5, 9:35 AM EDTFulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend revers
- Zacks · Jun 3, 11:00 AM EDTFULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's EndFulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.
- BNK Invest · Jun 2, 3:20 PM EDTNotable Tuesday Option Activity: CWT, AVGO, FULCLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in California Water Service Group (Symbol: CWT), where a total volume of 8,452 contracts has been traded thus far today, a contract volume which is representative o
- RTTNews · Jun 2, 8:41 AM EDTPre-Market Movers: BJDX, PMI, SBFM Drive Momentum(RTTNews) – Biotech stocks are showing strong pre-market moves this Tuesday, hinting at possible breakout setups.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Fulcrum Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.